Therapeutic Insights
Filter News
Found 994 articles
-
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.” -
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report. -
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ... -
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv... -
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract. -
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im... -
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook. -
While donanemab showed impressive results in Phase III TRAILBLAZER-ALZ 2, concerns regarding its safety remain compared with Biogen’s and Eisai’s Leqembi. -
Quest Diagnostics Extends Alzheimer's Disease Portfolio with New AI-Powered Test Service from uMETHOD Health
5/4/2023
Quest Diagnostics today announced nationwide availability of the RestoreU ™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline.
-
The amyloid plaque targeting therapy met primary endpoint and all secondary endpoints, which Lilly will use in its submission to the FDA this quarter. -
ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab
5/3/2023
The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported today by Eli Lilly and Company for their amyloid-clearing antibody donanemab.
-
Alzheimer's Association Statement on Donanemab Phase 3 Topline Data Release
5/3/2023
On behalf of the millions of Americans impacted by the devastation of Alzheimer's disease, the Alzheimer's Association enthusiastically welcomes the robustly positive topline data reported by Eli Lilly on the TRAILBLAZER-ALZ2 Phase 3 clinical trial of donanemab for the treatment of early symptomatic Alzheimer's disease.
-
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
5/2/2023
SciSparc Ltd today announced that the last patient enrolled in the Company's Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation, completed its treatment.
-
Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’s Disease With a Proprietary formulation Based On 5-MeO-DMT
4/25/2023
Biomind Labs Inc. is pleased to announce that it has commenced a Phase II clinical trial for its proprietary 5-Metoxi-N,N-dimethyltryptamine (" 5-MeO-DMT ")-based BMND08 candidate, a sublingual formulation for the potential treatment of anxiety and depression in Alzheimer’s disease.
-
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
4/24/2023
ProMIS Neurosciences Inc. today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company’s lead candidate for AD, PMN310.
-
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
4/20/2023
Tiziana Life Sciences Ltd. today announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer’s Disease in Q2 2023.
-
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases
4/20/2023
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD ™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases.
-
ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST
4/19/2023
Annovis Bio, Inc. today announced that patient recruitment for the Company's Phase 2/3 study of buntanetap for the treatment of moderate Alzheimer's disease (AD) remains consistent with its planned development program.
-
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders Data to Support Alzheimer’s Study
4/19/2023
Silo Pharma, Inc. announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD.
-
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
4/19/2023
DBV Technologies announced that DBV has received written responses from the U.S. Food and Drug Administration on the regulatory path for investigational Viaskin™ Peanut 250 μg patch in toddlers ages 1 – 3 years-old with a confirmed peanut allergy.